Please login to the form below
Editas Medicine
This page shows the latest Editas Medicine news and features for those working in and with pharma, biotech and healthcare.
Allergan and Editas claim a CRISPR first in inherited blindness study
Allergan and Editas Medicine have made history after scientists used a CRISPR treatment developed by the partners to edit cells inside the human body. ... treatment. Allergan and Editas plan to treat a further 18 LCA10 patients with EDIT-101, to evaluate
Latest news
-
Trial dents confidence in Sangamo’s gene-editing tech
Companies developing other gene-editing technologies, such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine, also saw their shares close down, suggesting a knee-jerk reaction in the sell-off.
-
Editas CEO exits the CRISPR firm ahead of first clinical trial
Shares in company and competitors sink. Gene-editing specialist Editas Medicine will have to start its first CRISPR clinical trial without the direction of president and CEO Katrine Bosley, who has ... The multiple departures and the timing of Bosley’s
-
Sangamo’s first gene-editing trial doesn’t convince investors
Principal investigator Joseph Muenzer of the University of North Carolina (UNC) School of Medicine in Chapel Hill described those reductions are encouraging, saying: “We hope to understand the clinical relevance of ... But companies developing other
-
Allergan builds on gene editing deal
The Allergan team is excited to work with colleagues at Editas Medicine to develop EDIT-101 and potentially deliver a transformative medicine for LCA10 patients.". ... These developments have caused the shares of leaders in the field, CRISPR Therapeutics,
-
Bayer forms JV with gene editing firm CRISPR
CRISPR was formed by a team led by Emmanuelle Charpentier, who was awarded the Janssen Award for Biomedical Research last year - along with Jennifer Doudna of Editas Medicine - for the discovery
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
2019: CRISPR and therapeutic gene editing comes of age
In November, the US Food and Drug Administration (FDA) approved Editas Medicine’s Investigational New Drug (IND) application for a phase 1/2 trial of its Allergan-partnered CRISPR drug ... Editas, and the failure of Sangamo Therapeutics’ rival
-
Cutting through the noise: CRISPR
EDIT-101 is an experimental CRISPR genome-editing medicine that is currently being investigated by Editas for the treatment of Leber congenital amaurosis 10 (LCA10), an inherited eye condition. ... Editas Medicine and partner Allergan plan to initiate a
-
Deal Watch March 2017
Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other
-
Deal Watch May 2016
This follows the $94m IPO of Editas Medicine in February this year.
-
Deal Watch October 2015
companies. Other biotechs exploiting the CRISPR/Cas-9 technology for the development of therapeutics include Editas Medicine, Intellia Therapeutics and Caribou Biosciences; both Novartis and AstraZeneca have already developed collaborations in
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
New hires at Abbott, Kite and Arrakis Therapeutics
Most recently, Bosley served as the chief executive officer of Editas Medicine, and previously worked as CEO of Avila Therapeutics until its acquisition by Celgene.
-
Editas Medicine names James Mullen as chairman
He has previously served as CEO of Patheon. Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors. ... Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned
-
Editas Medicine adds to its board of directors
Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board's audit committee. ... She said: “I am honoured to join Editas Medicine’s board of directors. “
-
Editas Medicine adds to board of directors
Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... Katrine Bosley, Editas Medicine's president and chief executive officer, said: “I am
More from appointments
Approximately 3 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
